To confirm that inhibition of HIF-1α resulted in upregulation of NFκB in hypoxic breast cancer cells in the presence of IL-1β, we decided to perform similar experiments by using Topotecan, a topoisomerase inhibitor which has been described also as a pharmacological inhibitor of HIF-1α [31]. This evidence concerns the gene HIF1A and breast carcinoma.